Articles mentioning Bristol-Myers Squibb Co. (BMY)

Results 11 - 20 of 831 : Previous 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for BMY

Investing | April 13, 2016

What Caused Arrowhead Pharmaceuticals to Skyrocket 13% Today

New data from its trial of ARC-520 in hepatitis B ignited a rally.

Investing | April 13, 2016

3 Biotech Takeover Targets That Could Get Bought Soon

Kite Pharma, Medivation, Inc., and Portola Pharmaceuticals could all have suitors knocking on their door.

Investing | April 12, 2016

3 Nominations for Big Pharma's Riskiest Pipeline -- and Why They Qualify

Understanding the level of risk in a therapeutic pipeline leads to smarter investing. Our contributors tip you off on where to be wary, and what benchmarks to look for.

Investing | April 07, 2016

3 Drug Developers Pfizer Could Go After Now That the Allergan Deal Is Officially Dead

With Allergan now in the rearview mirror, Pfizer may seek to the move the needle by acquiring one of these three drug developers.

Investing | April 07, 2016

Ignore Exelixis, Inc.: Here Are 3 Better Stocks

Whether you want to stay with oncology or try your hand at antivirals or very small medical devices, any one of these three stocks is better than Exelixis.

Investing | March 31, 2016

3 Reasons Investors Can Buy Bristol-Myers Squibb

Fast-growing immuno-oncology and anticoagulant drugs and top-tier financials make this one company investors ought to consider buying.

Investing | March 15, 2016

Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb

After Exelexis' recent market beat-down, is it a better buy than the big pharma that fell off a patent cliff?

Investing | March 14, 2016

3 Megacap Stocks With 5-Year Projected Earnings Growth Rates Above 20%

Who ever said big businesses have to grow at a snail's pace?

Investing | February 20, 2016

Is This the Company Gilead Sciences Should Fear Most? (Hint: It's Not Merck or AbbVie)

A novel new hepatitis C drug under development at Regulus Therapeutics just put up impressive mid stage interim trial results.

Investing | February 16, 2016

Bristol-Myers Squibb Co Stock in 4 Charts

The immuno-oncology pioneer is quickly recovering from its fall off the patent cliff.

Results 11 - 20 of 831 : Previous 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for BMY